Previous 10 | Next 10 |
Gainers: Ameri Holdings (NASDAQ: AMRH ) +152% . More news on: Ameri Holdings, Inc., Westwater Resources, Inc., Genius Brands International, Inc., Stocks on the move, , Read more ...
SOUTH SAN FRANCISCO, Calif. , May 19, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics, announce...
SOUTH SAN FRANCISCO, Calif. , May 15, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA) is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The c...
IDEAYA Biosciences (NASDAQ: IDYA ): Q1 GAAP EPS of -$0.59 misses by $0.02 . More news on: IDEAYA Biosciences, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
SOUTH SAN FRANCISCO, Calif. , May 12, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics, provided a bu...
SOUTH SAN FRANCISCO, Calif. , April 21, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics, announ...
Stating the obvious, Baird analysts have created three lists of healthcare companies that may be worth a look considering their attractive valuations or relatively strong capitalizations amid the COVID-19 selloff. More news on: IDEAYA Biosciences, Inc., Surface Oncology, Inc., Jounce Thera...
IDEAYA Biosciences (NASDAQ: IDYA ): Q4 GAAP EPS of -$0.53 beats by $0.03 . More news on: IDEAYA Biosciences, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
SOUTH SAN FRANCISCO, Calif. , March 24, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics, provid...
IDEAYA Biosciences (NASDAQ: IDYA ) will collaborate with Pfizer (NYSE: PFE ) on a clinical trial evaluating the combination of IDE196, a protein kinase C inhibitor, and the latter's binimetinib, a MEK inhibitor, in patients with GNA11 hotspot-mutated solid tumors, including metastatic...
News, Short Squeeze, Breakout and More Instantly...
IDEAYA Biosciences Inc. Company Name:
IDYA Stock Symbol:
NASDAQ Market:
IDEAYA Biosciences Inc. Website:
IDEAYA Biosciences to Participate in Upcoming August 2024 Investor Relations Event PR Newswire SOUTH SAN FRANCISCO, Calif. , July 29, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery an...
2024-07-10 16:15:02 ET RBC Capital analyst issues OUTPERFORM recommendation for IDYA on July 10, 2024 02:51PM ET. The previous analyst recommendation was Outperform. IDYA was trading at $37.33 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
2024-07-10 16:00:03 ET Gregory Renza from RBC Capital issued a price target of $61.00 for IDYA on 2024-07-10 14:51:00. The adjusted price target was set to $61.00. At the time of the announcement, IDYA was trading at $37.33. The overall price target consensus is at $35.3...